Zai Lab Limited, a biopharmaceutical company listed on the Hong Kong Stock Exchange and NASDAQ, has announced the grant of Restricted Share Units under its 2024 Equity Incentive Plan. On May 12, 2025, U.S. Eastern Time, the company awarded 9,800 American Depositary Shares (ADSs) to two grantees. Following this allocation, 82,686,733 shares remain available for future grants under the plan. This move is part of the company's ongoing efforts to align with its equity compensation strategy, as approved during the 2024 annual general meeting of shareholders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief on May 14, 2025, and is solely responsible for the information contained therein.